Zobrazeno 1 - 10
of 32
pro vyhledávání: '"HYEONG SIM CHOI"'
Publikováno v:
Pharmaceuticals, Vol 15, Iss 6, p 704 (2022)
Cisplatin-based chemotherapy has been effectively used to treat oral cancer, but treatment often fails owing to the development of drug resistance. However, the important gene expression alterations associated with these resistances remain unclear. I
Externí odkaz:
https://doaj.org/article/5ed283c6877f44f1b97f3aa37b12b4bf
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 15
International Journal of Molecular Sciences, Vol 22, Iss 8167, p 8167 (2021)
Volume 22
Issue 15
International Journal of Molecular Sciences, Vol 22, Iss 8167, p 8167 (2021)
Cisplatin is among the most widely used anticancer drugs used in the treatment of several malignancies, including oral cancer. However, cisplatin treatment often promotes chemical resistance, subsequently causing treatment failure. Several studies ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ea2b5aaa8457b82c2dfa3e503726de8
http://europepmc.org/articles/PMC8348335
http://europepmc.org/articles/PMC8348335
Publikováno v:
Molecular Biology Reports. 48:7057-7057
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e111209af7c7369a12c58b0b734424d7
https://doi.org/10.1007/s11033-021-06651-z
https://doi.org/10.1007/s11033-021-06651-z
Publikováno v:
International Journal of Molecular Sciences
Volume 20
Issue 12
International Journal of Molecular Sciences, Vol 20, Iss 12, p 3034 (2019)
Volume 20
Issue 12
International Journal of Molecular Sciences, Vol 20, Iss 12, p 3034 (2019)
Cisplatin is one of the major drugs used in oral cancer treatments, but its usage can be limited by acquired drug resistance. In this study, we established three cisplatin-resistant oral squamous cell carcinoma (OSCC) cell lines and characterized the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b31877d147924c2f3ad78d879bf2db
http://europepmc.org/articles/PMC6627081
http://europepmc.org/articles/PMC6627081
Autor:
MIN KYOUNG KIM1, HYEONG SIM CHOI1, SUNG-GOOK CHO2 chosg@ut.ac.kr, YONG CHEOL SHIN1, SEONG-GYU KO1 epiko@khu.ac.kr
Publikováno v:
Molecular Medicine Reports. 2016, Vol. 13 Issue 5, p4065-4072. 8p.
Autor:
Seong-Gyu Ko, Seung Hee Moon, Min Kyoung Kim, Hee Jae Lee, Hyeong Sim Choi, Hee Jae Jang, Sung-Gook Cho
Publikováno v:
Molecular and Cellular Biochemistry. 426:1-8
Paclitaxel is an anti-cancer drug for treating cancer, but paclitaxel resistance is reported in cancer cells. Multidrug resistance (MDR) is related with the epithelial-to-mesenchymal transition (EMT) mechanism, which plays a key role in cancer metast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb4ee84e7d656d1c15c67dc406f661d6
https://doi.org/10.1007/s11010-016-2875-y
https://doi.org/10.1007/s11010-016-2875-y
Autor:
Sung-Gook Cho, Min-Soo Kim, Ilhwan Kim, Hyeong Sim Choi, Seong-Gyu Ko, Seung Hee Moon, Min Kyoung Kim
Publikováno v:
Phytotherapy Research. 30:2020-2026
Angelica gigas Nakai (AGN, Korean Dang-gui) is traditionally used for the treatment of various diseases including cancer. Here, we investigated multidrug-resistant phenotype-reversal activities of AGN and its compounds (decursin, ferulic acid, and no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd4b1dec044acec66b5a7d59a788a726
https://doi.org/10.1002/ptr.5708
https://doi.org/10.1002/ptr.5708
Autor:
Hyun Woo Kim, Daejin Kim, Hyeong Sim Choi, Yong Sang Hong, Dong‑Hoon Jin, Yeong Seok Kim, Seul Lee, Ih‑Yeon Hwang, Soo‑A Jung, Seong-Gyu Ko, Jung Shin Lee, Tae Won Kim, Dae Hee Lee, Kim Kyu Pyo, Jeong Hee Kim, Kim Seung Mi, Hyo In Kim, Moon Jai Hee, Jae Sik Shin, Eun Kyoung Choi, Eun Young Lee, Seung-Woo Hong, Jeong Eun Kim, Youn Kyung Choi, Sung Gook Cho, Won-Keun Lee
Publikováno v:
Molecular Medicine Reports. 14:3955-3960
Triple-negative breast cancer (TNBC) is a breast cancer subtype that has an aggressive phenotype, is highly metastatic, has limited treatment options and is associated with a poor prognosis. In addition, metastatic TNBC has no preferred standard chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350734b02e396b12060f756fe3a95862
https://doi.org/10.3892/mmr.2016.5722
https://doi.org/10.3892/mmr.2016.5722
Publikováno v:
Molecular Medicine Reports. 13:4065-4072
Cancer cells can acquire an anticancer, drug-resistant phenotype following chemotherapy, which is tightly linked to cancer malignancy and patient survival rates. Therefore, the identification of options to treat chemotherapy‑resistant cancer cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e847b00cd973a8af1c6359ddb95c193
https://doi.org/10.3892/mmr.2016.4996
https://doi.org/10.3892/mmr.2016.4996
Autor:
Kang Min Lee, Kangwook Lee, Seong-Gyu Ko, Min Kyoung Kim, Hyeong Sim Choi, Sung-Gook Cho, Yong Cheol Shin
Publikováno v:
Oncotarget
Tumor growth requires a process called angiogenesis, a new blood vessel formation from pre-existing vessels, as newly formed vessels provide tumor cells with oxygen and nutrition. Danggui-Sayuk-Ga-Osuyu-Saenggang-Tang (DSGOST), one of traditional Chi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a7506d4149990cf3666b263dd21f99e
http://europepmc.org/articles/PMC5008322
http://europepmc.org/articles/PMC5008322